Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
- Conditions
- Ovarian Neoplasms
- Interventions
- First Posted Date
- 2006-11-07
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 16
- Registration Number
- NCT00396591
- Locations
- 🇸🇪
Sanofi-Aventis Administrative Office, Bromma, Sweden
Efficacy Study of Pristinamycin Versus Amoxicillin to Treat Tonsillitis Induced by Streptococcus in Children
- First Posted Date
- 2006-10-29
- Last Posted Date
- 2009-03-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 395
- Registration Number
- NCT00393744
- Locations
- 🇫🇷
Sanofi-Aventis, Paris, France
Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children
- Conditions
- Orthomyxoviridae InfectionInfluenzaMyxovirus Infection
- Interventions
- Biological: Split, Inactivated, Trivalent Influenza VaccineBiological: Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)
- First Posted Date
- 2006-10-24
- Last Posted Date
- 2011-12-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 520
- Registration Number
- NCT00391391
Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial)
- Conditions
- Diabetes Mellitus, Type 1
- First Posted Date
- 2006-10-20
- Last Posted Date
- 2010-08-31
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 2346
- Registration Number
- NCT00390728
An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder
- First Posted Date
- 2006-10-20
- Last Posted Date
- 2016-05-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 428
- Registration Number
- NCT00390533
- Locations
- 🇦🇺
Sanofi-Aventis Administrative Office, Macquarie Park, Australia
A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder
- Conditions
- Anxiety
- First Posted Date
- 2006-10-20
- Last Posted Date
- 2011-04-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 366
- Registration Number
- NCT00390650
- Locations
- 🇨🇦
Sanofi-Aventis, Laval, Canada
Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects
- Conditions
- Orthomyxoviridae InfectionInfluenzaMyxovirus Infection
- Interventions
- Biological: Split, Inactivated, Trivalent Influenza Vaccine
- First Posted Date
- 2006-10-17
- Last Posted Date
- 2012-04-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 817
- Registration Number
- NCT00388583
Efficacy and Safety of Dianicline Treatment as an Aid to Smoking Cessation in Cigarette Smokers (AMERIDIAN)
- Conditions
- Smoking CessationTobacco Use Cessation
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 630
- Registration Number
- NCT00387946
- Locations
- 🇨🇦
Administrative Office, Laval, Quebec, Canada
Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer
- Conditions
- Advanced Breast CancerBreast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2016-05-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 6
- Registration Number
- NCT00387907
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Malvern, Pennsylvania, United States
XRP9881 in Combination With Trastuzumab in Metastatic Breast Cancer
- Conditions
- Breast Neoplasms
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 51
- Registration Number
- NCT00386685
- Locations
- 🇨🇭
Sanofi-Aventis Administrative Office, Geneva, Switzerland